Nr 1, 2023: Hjärnhälsa

[1] https://drtalks.com/overcoming-long-haul-syndrome-summit-2023/

2 Gomes Gonçalves N, Vidal Ferreira N, Khandpur N, Martinez Steele E, Bertazzi Levy R, Andrade Lotufo P, Bensenor IM, Caramelli P, Alvim de Matos SM, Marchioni DM, Suemoto CK. Association Between Consumption of Ultraprocessed Foods and Cognitive Decline. JAMA Neurol. 2023 Feb 1;80(2):142-150.

3 Moir RD, Lathe R, Tanzi RE. The antimicrobial protection hypothesis of Alzheimer’s disease. Alzheimers Dement. 2018 Dec;14(12):1602-1614.

4 65% of those affected are women1. 1 Prince MA., 2014. World Alzheimer Report 2014 United Kingdom: Alzheimer’s Disease International.

5Ghahremani M, Smith EE, Chen HY, Creese B, Goodarzi Z, Ismail Z. Vitamin D supplementation and incident dementia: Effects of sex, APOE, and baseline cognitive status. Alzheimers Dement (Amst). 2023 Mar 1;15(1):e12404.

6 An Y, Varma VR, Varma S, Casanova R, Dammer E, Pletnikova O, Chia CW, Egan JM, Ferrucci L, Troncoso J, Levey AI, Lah J, Seyfried NT, Legido-Quigley C, O’Brien R, Thambisetty M. Evidence for brain glucose dysregulation in Alzheimer’s disease. Alzheimers Dement. 2018 Mar;14(3):318-329..

7 Piller C. Revised clinical trial form for Alzheimer’s antibody warned of fatal brain bleeds. Science 2022-12-30. https://www.science.org/content/article/revised-clinical-trial-form-alzheimer-s-antibody-warned-fatal-brain-bleeds

8 Dale Bredesens Facebook-sida, 1 dec 2022.

9 Sala-Vila A, Satizabal CL, Tintle N, Melo van Lent D, Vasan RS, Beiser AS, Seshadri S, Harris WS. Red Blood Cell DHA Is Inversely Associated with Risk of Incident Alzheimer’s Disease and All-Cause Dementia: Framingham Offspring Study. Nutrients. 2022 Jun 9;14(12):2408

10 Sala-Vila A, Arenaza-Urquijo EM, Sánchez-Benavides G, Suárez-Calvet M, Milà-Alomà M, Grau-Rivera O, González-de-Echávarri JM, Crous-Bou M, Minguillón C, Fauria K, Operto G, Falcón C, Salvadó G, Cacciaglia R, Ingala S, Barkhof F, Schröder H, Scarmeas N, Gispert JD, Molinuevo JL; ALFA study. DHA intake relates to better cerebrovascular and neurodegeneration neuroimaging phenotypes in middle-aged adults at increased genetic risk of Alzheimer disease. Am J Clin Nutr. 2021 Jun 1;113(6):1627-1635.

11 Weaver DF et al. Alzheimer’s disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites. Alzheimers Dement (N Y). 2022 Apr 6;8(1):e12283.

12 Moir RD, Lathe R, Tanzi RE. The antimicrobial protection hypothesis of Alzheimer’s disease. Alzheimers Dement. 2018 Dec;14(12):1602-1614.

[1]3 Wu C, Jiang ML, Jiang R, Pang T, Zhang CJ. The roles of fungus in CNS autoimmune and neurodegeneration disorders. Front Immunol. 2023 Jan 26;13:1077335.

14 Benson D. Conversation with Dale Bredesen, MD. Integr Med (Encinitas). 2021 Oct;20(5):44-47.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594968/

[1]5 Rao et al. 2021. ReCODE: A Personalized, Targeted, Multi-Factorial Therapeutic Program for Reversal of Cognitive Decline https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533598/

[1]6 Fitzgerald KN, Hodges R, Hanes D, Stack E, Cheishvili D, Szyf M, Henkel J, Twedt MW, Giannopoulou D, Herdell J, Logan S, Bradley R. Potential reversal of epigenetic age using a diet and lifestyle intervention: a pilot randomized clinical trial. Aging. 2021 13(7), 9419–9432.

[1]7 Martin P, Sandström H. Föryngring inom räckhåll – så minskar du din biologiska ålder. Hälsa & Funktionsmedicin nr 2 2002.

Azevedo FA, Carvalho LR, Grinberg LT, Farfel JM, Ferretti RE, Leite RE, Jacob Filho W, Lent R, Herculano-Houzel S. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J Comp Neurol. 2009 Apr 10;513(5):532-41. doi: 10.1002/cne.21974. PMID: 19226510.

1. Chang CY, Ke DS, Chen JY. Essential fatty acids and human brain. Acta Neurol Taiwan. 2009 Dec;18(4):231-41. PMID: 20329590.

2. Ventriglio A, Sancassiani F, Contu MP, Latorre M, Di Slavatore M, Fornaro M, Bhugra D. Mediterranean Diet and its Benefits on Health and Mental Health: A Literature Review. Clin Pract Epidemiol Ment Health. 2020 Jul 30;16(Suppl-1):156-164. doi: 10.2174/1745017902016010156. PMID: 33029192; PMCID: PMC7536728.

3. Yin W, Löf M, Chen R, Hultman CM, Fang F, Sandin S. Mediterranean diet and depression: a population-based cohort study. Int J Behav Nutr Phys Act. 2021 Nov 27;18(1):153. doi: 10.1186/s12966-021-01227-3. PMID: 34838037; PMCID: PMC8627099.

4. Kaddoumi A, Denney TS Jr, Deshpande G, Robinson JL, Beyers RJ, Redden DT, Praticò D, Kyriakides TC, Lu B, Kirby AN, Beck DT, Merner ND. Extra-Virgin Olive Oil Enhances the Blood-Brain Barrier Function in Mild Cognitive Impairment: A Randomized Controlled Trial. Nutrients. 2022 Dec 1;14(23):5102. doi: 10.3390/nu14235102. PMID: 36501136; PMCID: PMC9736478.

5. Sánchez-Villegas A, Verberne L, De Irala J, Ruíz-Canela M, Toledo E, Serra-Majem L, Martínez-González MA. Dietary fat intake and the risk of depression: the SUN Project. PLoS One. 2011 Jan 26;6(1):e16268. doi: 10.1371/journal.pone.0016268. PMID: 21298116; PMCID: PMC3027671.

6. Perona JS, Vögler O, Sánchez-Domínguez JM, Montero E, Escribá PV, Ruiz-Gutierrez V. Consumption of virgin olive oil influences membrane lipid composition and regulates intracellular signaling in elderly adults with type 2 diabetes mellitus. J Gerontol A Biol Sci Med Sci. 2007 Mar;62(3):256-63. doi: 10.1093/gerona/62.3.256. PMID: 17389722.

7. Hac-Wydro K, Wydro P. The influence of fatty acids on model cholesterol/phospholipid membranes. Chem Phys Lipids. 2007 Nov;150(1):66-81. doi: 10.1016/j.chemphyslip.2007.06.213. Epub 2007 Jun 21. PMID: 17651712.

8. Sakamoto T, Cansev M, Wurtman RJ. Oral supplementation with docosahexaenoic acid and uridine-5′-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res. 2007 Nov 28;1182:50-9. doi: 10.1016/j.brainres.2007.08.089. Epub 2007 Sep 21. PMID: 17950710; PMCID: PMC2140951.

9. Rangel-Huerta, O. D., & Gil, A. (2017). Effect of omega-3 fatty acids on cognition: an updated systematic review of randomized clinical trials. Nutrition Reviews, 76(1), 1–20. doi:10.1093/nutrit/nux064

10. Petermann AB, Reyna-Jeldes M, Ortega L, Coddou C, Yévenes GE. Roles of the Unsaturated Fatty Acid Docosahexaenoic Acid in the Central Nervous System: Molecular and Cellular Insights. Int J Mol Sci. 2022 May 12;23(10):5390. doi: 10.3390/ijms23105390. PMID: 35628201; PMCID: PMC9141004.

11. Hoepner CT, McIntyre RS, Papakostas GI. Impact of Supplementation and Nutritional Interventions on Pathogenic Processes of Mood Disorders: A Review of the Evidence. Nutrients. 2021 Feb 26;13(3):767. doi: 10.3390/nu13030767. PMID: 33652997; PMCID: PMC7996954.

12. Borsini A, Nicolaou A, Camacho-Muñoz D, Kendall AC, Di Benedetto MG, Giacobbe J, Su KP, Pariante CM. Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis. Mol Psychiatry. 2021 Nov;26(11):6773-6788. doi: 10.1038/s41380-021-01160-8. Epub 2021 Jun 16. PMID: 34131267; PMCID: PMC8760043.

13. Saher G, Brügger B, Lappe-Siefke C, Möbius W, Tozawa R, Wehr MC, Wieland F, Ishibashi S, Nave KA. High cholesterol level is essential for myelin membrane growth. Nat Neurosci. 2005 Apr;8(4):468-75. doi: 10.1038/nn1426. Epub 2005 Mar 27. PMID: 15793579.

14. Penesová A, Dean Z, Kollár B, Havranová A, Imrich R, Vlček M, Rádiková Ž. Nutritional intervention as an essential part of multiple sclerosis treatment? Physiol Res. 2018 Aug 16;67(4):521-533. doi: 10.33549/physiolres.933694. Epub 2018 May 10. PMID: 29750884.

15. Chauhan A, Chauhan V. Beneficial Effects of Walnuts on Cognition and Brain Health. Nutrients. 2020 Feb 20;12(2):550. doi: 10.3390/nu12020550. PMID: 32093220; PMCID: PMC7071526.

16. Visioli F, Risé P, Barassi MC, Marangoni F, Galli C. Dietary intake of fish vs. formulations leads to higher plasma concentrations of n-3 fatty acids. Lipids. 2003 Apr;38(4):415-8. doi: 10.1007/s11745-003-1077-x. PMID: 12848287.

17. Jackowski SA, Alvi AZ, Mirajkar A, Imani Z, Gamalevych Y, Shaikh NA, Jackowski G. Oxidation levels of North American over-the-counter n-3 (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety. J Nutr Sci. 2015 Nov 4;4:e30. doi: 10.1017/jns.2015.21. PMID: 26688721; PMCID: PMC4678768.

18. Albert BB, Cameron-Smith D, Hofman PL, Cutfield WS. Oxidation of marine omega-3 supplements and human health. Biomed Res Int. 2013;2013:464921. doi: 10.1155/2013/464921. Epub 2013 Apr 30. PMID: 23738326; PMCID: PMC3657456.

19. Mason RP, Sherratt SCR. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. Biochem Biophys Res Commun. 2017 Jan 29;483(1):425-429. doi: 10.1016/j.bbrc.2016.12.127. Epub 2016 Dec 21. PMID: 28011269.

20. Bossenmeyer-Pourié C, Smith AD, Lehmann S, Deramecourt V, Sablonnière B, Camadro JM, Pourié G, Kerek R, Helle D, Umoret R, Guéant-Rodriguez RM, Rigau V, Gabelle A, Sequeira JM, Quadros EV, Daval JL, Guéant JL. N-homocysteinylation of tau and MAP1 is increased in autopsy specimens of Alzheimer’s disease and vascular dementia. J Pathol. 2019 Jul;248(3):291-303. doi: 10.1002/path.5254. Epub 2019 Mar 19. PMID: 30734924.

21. Jakubowski. Homocysteine Modification in Protein Structure/Function and Human Disease. Physiol Rev. 2019 Jan 1, 99 (1), 555-604

22. Yu JT, Xu W, Tan CC, Andrieu S, Suckling J, Evangelou E, Pan A, Zhang C, Jia J, Feng L, Kua EH, Wang YJ, Wang HF, Tan MS, Li JQ, Hou XH, Wan Y, Tan L, Mok V, Tan L, Dong Q, Touchon J, Gauthier S, Aisen PS, Vellas B. Evidence-based prevention of Alzheimer’s disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1201-1209. doi: 10.1136/jnnp-2019-321913. Epub 2020 Jul 20. PMID: 32690803; PMCID: PMC7569385.

23. Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, Smith AD. Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9523-8. doi: 10.1073/pnas.1301816110. Epub 2013 May 20. PMID: 23690582; PMCID: PMC3677457.

24. Dawson SL, Bowe SJ, Crowe TC. A combination of omega-3 fatty acids, folic acid and B-group vitamins is superior at lowering homocysteine than omega-3 alone: A meta-analysis. Nutr Res. 2016 Jun;36(6):499-508. doi: 10.1016/j.nutres.2016.03.010. Epub 2016 Apr 1. PMID: 27188895.

25. Li M, Li W, Gao Y, Chen Y, Bai D, Weng J, Du Y, Ma F, Wang X, Liu H, Huang G. Effect of folic acid combined with docosahexaenoic acid intervention on mild cognitive impairment in elderly: a randomized double-blind, placebo-controlled trial. Eur J Nutr. 2021 Jun;60(4):1795-1808. doi: 10.1007/s00394-020-02373-3. Epub 2020 Aug 28. PMID: 32856190.

26. van Soest APM, van de Rest O, Witkamp RF, Cederholm T, de Groot LCPGM. DHA status influences effects of B-vitamin supplementation on cognitive ageing: a post-hoc analysis of the B-proof trial. Eur J Nutr. 2022 Oct;61(7):3731-3739. doi: 10.1007/s00394-022-02924-w. Epub 2022 Jun 15. PMID: 35704085; PMCID: PMC9464144.

27. Maltais M, de Souto Barreto P, Bowman GL, Smith AD, Cantet C, Andrieu S, Rolland Y. Omega-3 Supplementation for the Prevention of Cognitive Decline in Older Adults: Does It Depend on Homocysteine Levels? J Nutr Health Aging. 2022;26(6):615-620. doi: 10.1007/s12603-022-1809-5. PMID: 35718871.

28. Jernerén F, Elshorbagy AK, Oulhaj A, Smith SM, Refsum H, Smith AD. Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial. Am J Clin Nutr. 2015 Jul;102(1):215-21. doi: 10.3945/ajcn.114.103283. Epub 2015 Apr 15. PMID: 25877495.

1,2https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1323154/

3.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2775644/

4.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389700/

[1] Natoli, J. L. et al. (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia, 30, 599–609.

[1] Gazerani, P. (2020) Migraine and diet. Nutrients, 12 (6), 1658.

[1] Ashina, M. et al. (2021) Migraine: disease characterisation, biomarkers, and precision medicine. Lancet, 397 (10 283), 1496−1504.

[1] Younger, D. S. (2016) Epidemiology of migraine. Neurol. Clin., 34 (4), 849−861

[1] Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L. & Stewart, W. F.; AMPP Advisory Group (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 68 (5), 343−349.

[1] Karsan, N. & Goadsby, P. J. (2018) Biological insights from the premonitory symptoms of migraine. Nat. Rev. Neurol., 14 (12), 699−710.

[1] Rattanawong, W., Rapoport, A. & Srikiatkhachorn, A. (2022) Neurobiology of migraine progression. Neurobiol. Pain, 12, 100 094.

[1] Goschorska, M., Gutowska, I., Baranowska-Bosiacka, I., Barczak, K. & Chlubek, D. (2020) The use of antioxidants in the treatment of migraine. Antioxidants (Basel), 9 (2), 116.

[1] Lippi, G., Mattiuzzi, C. & Cervellin, G. (2014) C-reactive protein and migraine. Facts or speculations? Clin. Chem. Lab. Med., 52 (9), 1265−1272.

[1] Rainero, I., Govone, F., Gai, A., Vacca, A. & Rubino, E. (2018) Is migraine primarily a metaboloendocrine disorder? Curr. Pain Headache Rep., 22 (5), 36.

[1] Dodick, D. W. (2018) A phase-by-phase review of migraine pathophysiology. Headache, 58 (Suppl 1), 4−16.

[1] Peck, K. R., Johnson, Y. L. & Smitherman, T. A. (2016) Migraine. Handb. Clin. Neurol.,

138, 283−293.

[1] Bigal, M., Krymchantowski, A. V. & Lipton, R. B. (2009) Barriers to satisfactory migraine outcomes. What have we learned, where do we stand? Headache, 49 (7), 1028−1041.

[1] Sun-Edelstein, C. & Rapoport, A. M. (2016) Update on the pharmacological treatment of

chronic migraine. Curr. Pain Headache Rep., 20 (1), 6.

[1] Sun-Edelstein, C. & Mauskop, A. (2011) Alternative headache treatments: nutraceuticals, behavioral and physical treatments. Headache, 51, 469–483.

[1] Sun-Edelstein, C. & Mauskop, A. (2009) Foods and supplements in the management of

migraine headaches. Clin. J. Pain, 25 (5), 446−452.

[1] Robblee, J. & Starling, A. J. (2019) SEEDS for success: Lifestyle management in migraine. Cleve Clin. J. Med., 86 (11), 741−749.

[1] Marashly, E. T. & Bohlega, S. A. (2017) Riboflavin has neuroprotective potential: focus on Parkinson’s disease and migraine. Front. Neurol., 8, 333.

[1] Thompson, D. F. & Saluja, H. S. (2017) Prophylaxis of migraine headaches with riboflavin: A systematic review. J. Clin. Pharm. Ther., 42 (4), 394−403. doi: 10.1111/jcpt.12548.

[1]Condò, M., Posar, A., Arbizzani, A. & Parmeggiani, A. (2009) Riboflavin prophylaxis in pediatric and adolescent migraine. J. Headache Pain, 10 (5), 361−365. doi: 10.1007/s10194-009-0142-2.

[1]Talebian, A., Soltani, B., Banafshe, H. R., Moosavi, G. A., Talebian, M. & Soltani, S. (2018) Prophylactic effect of riboflavin on pediatric migraine: a randomized, double-blind, placebo-controlled trial. Electron Physician, 10 (2), 6279−6285. doi: 10.19082/6279.

[1]MacLennan, S. C., Wade, F. M., Forrest, K. M., Ratanayake, P. D., Fagan, E. & Antony, J. (2008) High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial. J. Child. Neurol., 23 (11), 1300−1304. doi: 10.1177/0883073808318053.

[1]Bruijn, J., Duivenvoorden, H., Passchier, J., Locher, H., Dijkstra, N. & Arts, W. F. (2010) Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial. Cephalalgia, 30 (12), 1426−1434. doi: 10.1177/0333102410365106.

[1]Condò, M., Posar, A., Arbizzani, A. & Parmeggiani, A. (2009) Riboflavin prophylaxis in pediatric and adolescent migraine. J. Headache Pain, 10 (5), 361−365. doi: 10.1007/s10194-009-0142-2.

[1]Schoenen, J., Lenaerts, M. & Bastings, E. (1994) High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia, 14 (5), 328−329. doi: 10.1046/j.1468-2982.1994.1405328.

[1]Schoenen, J., Jacquy, J. & Lenaerts, M. (1998) Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology, 50 (2), 466−470. doi: 10.1212/wnl.50.2.466.

[1]Rahimdel, A., Zeinali, A., Yazdian-Anari, P., Hajizadeh, R. & Arefnia, E. (2015) Effectiveness of vitamin B2 versus sodium valproate in migraine prophylaxis: a randomized clinical trial. Electron Physician, 7 (6), 1344−1348. doi: 10.14661/1344.

[1]Boehnke, C., Reuter, U., Flach, U., Schuh-Hofer, S., Einhäupl, K. M. & Arnold, G. (2004) High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur. J. Neurol., 11 (7), 475−477. doi: 10.1111/j.1468-1331.2004.00813.

[1]Di Lorenzo, C. et al. (2009) Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology, 72 (18), 1588−1594. doi: 10.1212/WNL.0b013e3181a41269.

[1]Prousky, J. & Seely, D. (2005) The treatment of migraines and tension-type headaches with intravenous and oral niacin (nicotinic acid): systematic review of the literature. Nutr. J., 4, 3. https://doi.org/10.1186/1475-2891-4-3.

[1]Prousky, J., Millman, C. G. & Kirkland, J. B. (2011) Pharmacologic use of niacin. J. Evid. Based Complement. Alternat. Med., 16 (2), 91−101. doi: 10.1177/2156587211399579.

[1]Prousky, J. & Sykes, E. (2003) Two case reports on the treatment of acute migraine with niacin. Its hypothetical mechanism of action upon calcitonin-gene related peptide and platelets. J. Orthomol. Med., 18, 108−110.

[1]Velling, D. A., Dodick, D. W. & Muir, J. J. (2003) Sustained-release niacin for prevention of migraine headache. Mayo Clin. Proc., 78 (6), 770−771. doi: 10.4065/78.6.770.

[1]Prousky, J. & Seely, D. (2005) The treatment of migraines and tension-type headaches with intravenous and oral niacin (nicotinic acid): systematic review of the literature. Nutr. J., 4, 3.

[1]Peracchi, M., Bamonti Catena, F., Pomati, M., De Franceschi, M. & Scalabrino, G. (2001) Human cobalamin deficiency: alterations in serum tumour necrosis factor-alpha and epidermal growth factor. Eur. J. Haematol., 67 (2), 123−127.

[1]van de Lagemaat, E. E., de Groot, L. C. P. G. M. & van den Heuvel, E. G. H. M. (2019) Vitamin B12 in relation to oxidative stress: a systematic review. Nutrients, 11 (2), 482.

[1]Togha, M., Razeghi Jahromi, S., Ghorbani, Z., Martami, F. & Seifishahpar, M. (2019) Serum vitamin B12 and methylmalonic acid status in migraineurs: a case-control study. Headache, 59 (9), 1492−1503.

[1]Urits, I. et al. (2020) Utilization of B12 for the treatment of chronic migraine. Best Pract. Res. Clin. Anaesthesiol., 34 (3), 479−491.

[1]van der Kuy, P. H., Merkus, F. W., Lohman, J. J., ter Berg, J. W. & Hooymans, P. M. (2002) Hydroxocobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open, pilot study. Cephalalgia, 22 (7), 513−519. doi: 10.1046/j.1468-2982.2002.00412.

[1]Calik, M. et al. (2018) The association between serum vitamin B12 deficiency and tension-type headache in Turkish children. Neurol. Sci., 39 (6), 1009−1014. doi: 10.1007/s10072-018-3286-5.

[1]Rainero, I., Vacca, A., Roveta, F., Govone, F., Gai, A. & Rubino, E. (2019) Targeting MTHFR for the treatment of migraines. Expert Opin. Ther. Targets, 23 (1), 29−37.

[1]Liampas, I. et al. (2020) Serum homocysteine, pyridoxine, folate, and vitamin B12 levels in migraine: systematic review and meta-analysis. Headache, 60 (8), 1508−1534.

[1]Liu, L., Yu, Y., He, J., Guo, L., Li, H. & Teng, J. (2019) Effects of MTHFR C677T and A1298C polymorphisms on migraine susceptibility: a meta-analysis of 26 studies. Headache, 59 (6), 891−905. doi: 10.1111/head.13540.

[1]Liampas, I. N. et al. (2020) Pyridoxine, folate and cobalamin for migraine: A systematic review. Acta Neurol. Scand., 142 (2), 108−120. doi: 10.1111/ane.13251.

[1]Lea, R., Colson, N., Quinlan, S., Macmillan, J. & Griffiths, L. (2009) The effects of vitamin supplementation and MTHFR (C677T) genotype on homocysteine-lowering and migraine disability. Pharmacogenet. Genomics, 19 (6), 422−428.

[1]Menon, S. et al. (2012) Genotypes of the MTHFR C677T and MTRR A66G genes act independently to reduce migraine disability in response to vitamin supplementation. Pharmacogenet. Genomics, 22 (10), 741−749.

[1]Menon, S. et al. (2015) Effects of dietary folate intake on migraine disability and frequency. Headache, 55 (2), 301−309. doi: 10.1111/head.12490.

[1]Bütün, A., Nazıroğlu, M., Demirci, S., Çelik, Ö. & Uğuz, A. C. (2015) Riboflavin and vitamin E increase brain calcium and antioxidants, and microsomal calcium-ATP-ase values in rat headache models induced by glyceryl trinitrate. J. Membr. Biol., 248 (2), 205−213.

[1]Ziaei, S., Kazemnejad, A. & Sedighi, A. (2009) The effect of vitamin E on the treatment of menstrual migraine. Med. Sci. Monit., 15 (1), CR16−CR19.

[1]Visser, E. J., Drummond, P. D. & Lee-Visser, J. L. A. (2020) Reduction in migraine and headache frequency and intensity with combined antioxidant prophylaxis (N-acetylcysteine, vitamin E, and vitamin C): a randomized sham-controlled pilot study. Pain Pract., 20 (7), 737−747.

[1]Ghorbani, Z. et al. (2019) Vitamin D in migraine headache: a comprehensive review on literature. Neurol. Sci., 40 (12), 2459−2477. doi: 10.1007/s10072-019-04021-z.

[1]Ghorbani, Z. et al. (2021) The effects of vitamin D3 supplementation on TGF-β and IL-17 serum levels in migraineurs: post hoc analysis of a randomized clinical trial. J. Pharm. Health Care Sci., 7 (1), 9.

[1]Ghorbani, Z. et al. (2020) The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial. J. Headache Pain, 21 (1), 22.

[1]Ghorbani, Z. et al. (2020) Vitamin D3 might improve headache characteristics and protect against inflammation in migraine: a randomized clinical trial. Neurol. Sci., 41 (5), 1183−1192.

[1]Nowaczewska, M., Wiciński, M., Osiński, S. & Kaźmierczak, H. (2020) The role of vitamin D in primary headache-from potential mechanism to treatment. Nutrients, 12 (1), 243. doi: 10.3390/nu12010243.

[1]Gazerani, P. et al. (2019) A randomized, double-blinded, placebo-controlled, parallel trial of vitamin D3 supplementation in adult patients with migraine. Curr. Med. Res. Opin., 35 (4), 715−723. doi: 10.1080/03007995.2018.1519503.

[1]Siniscalchi, A., Lochner, P., Cione, E., Michniewicz, A., Guidetti, V. & Gallelli, L. (2019) Improved efficacy of pregabalin by restoring plasma vitamin D levels in migraine: a case report. Psychopharmacol. Bull., 49 (2), 41−45.

[1]Dolati, S., Rikhtegar, R., Mehdizadeh, A. & Yousefi, M. (2020) The role of magnesium in pathophysiology and migraine treatment. Biol. Trace Elem. Res., 196 (2), 375−383. doi: 10.1007/s12011-019-01931-z.

[1]Kirkland, A. E., Sarlo, G. L. & Holton, K. F. (2018) The role of magnesium in neurological disorders. Nutrients, 10 (6), 730. doi: 10.3390/nu10060730.

[1]Ramadan, N. M., Halvorson, H., Vande-Linde, A., Levine, S. R., Helpern, J. A. & Welch, K. M. (1989) Low brain magnesium in migraine. Headache, 29 (9), 590−593. doi: 10.1111/j.1526-4610.1989.hed2909590.

[1]Sarchielli, P., Coata, G., Firenze, C., Morucci, P., Abbritti, G. & Gallai, V. (1992) Serum and salivary magnesium levels in migraine and tension-type headache. Results in a group of adult patients. Cephalalgia, 12 (1), 21−27.

[1]Assarzadegan, F., Asgarzadeh, S., Hatamabadi, H. R., Shahrami, A., Tabatabaey, A. & Asgarzadeh, M. (2016) Serum concentration of magnesium as an independent risk factor in migraine attacks: a matched case-control study and review of the literature. Int. Clin. Psychopharmacol., 31 (5), 287−292.

[1]Slavin, M., Li, H., Khatri, M. & Frankenfeld, C. (2021) Dietary magnesium and migraine in adults: A cross-sectional analysis of the National Health and Nutrition Examination Survey 2001−2004. Headache, 61 (2), 276−286.

[1]von Luckner, A. & Riederer, F. (2018) Magnesium in migraine prophylaxis-is there an evidence-based rationale? A systematic review. Headache, 58 (2), 199−209.

[1]Demirkaya, S., Vural, O., Dora, B. & Topçuoğlu, M. A. (2001) Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache, 41 (2), 171−177.

[1]Mauskop, A. & Varughese, J. (2012) Why all migraine patients should be treated with magnesium. J. Neural Transm. (Vienna), 119 (5), 575−579.

[1]Baratloo, A., Mirbaha, S., Delavar Kasmaei, H., Payandemehr, P., Elmaraezy, A. & Negida, A. (2017) Intravenous caffeine citrate vs. magnesium sulfate for reducing pain in patients with acute migraine headache; a prospective quasi-experimental study. Korean J. Pain, 30 (3), 176−182.

[1]Kandil, M. et al. (2021) MAGraine: Magnesium compared to conventional therapy for treatment of migraines. Am. J. Emerg. Med., 39, 28−33.

[1]Tayyebi, A., Poursadeghfard, M., Nazeri, M. & Pousadeghfard, T. (2019) Is there any correlation between migraine attacks and iron deficiency anemia? A case-control study. Int. J. Hematol. Oncol. Stem Cell Res., 13 (3), 164−171.

[1]Fallah, R., Zare Bidoki, S. & Ordooei, M. (2016) Evaluation efficacy of ferrous sulfate

therapy on headaches of 5-15 years old iron deficient children with migraine. Iran J. Ped. Hematol. Oncol., 6 (1), 32−37.

[1]Gholamreza-Mirzaee, M., Kheiri, S., Khosravi, Sh., Koshdel, A., Keyvani, Z. & Amini, Z. (2012) Iron therapy and migraine headache. J. Shahrekord Univ. Med. Sci., 13 (6), 56–62 [in Persian].

[1]Meng, S. H. et al. (2021) Association between dietary iron intake and serum ferritin and severe headache or migraine. Front. Nutr., 8, 685 564.

[1]Gonullu, H. et al. (2015) The levels of trace elements and heavy metals in patients with acute migraine headache. J. Pak. Med. Assoc., 65 (7), 694−697.

[1]Silva, M. L. et al. (2022) Decreased plasma levels and dietary intake of minerals in women with migraine. Nutr. Neurosci., 2022, 1−8 [published online ahead of print, Jun 3].

[1]Liu, H. Y., Gale, J. R., Reynolds, I. J., Weiss, J. H. & Aizenman, E. (2021) The multifaceted roles of zinc in neuronal mitochondrial dysfunction. Biomedicines, 9 (5), 489.

[1]Ahmadi, H. et al. (2020) Zinc supplementation affects favorably the frequency of migraine attacks: a double-blind randomized placebo-controlled clinical trial. Nutr. J., 19 (1), 101.

[1]Mazaheri, M., Aghdam, A. M., Heidari, M. & Zarrin, R. (2021) Assessing the effect of zinc supplementation on the frequency of migraine attack, duration, severity, lipid profile and hs-CRP in adult women. Clin. Nutr. Res., 10 (2), 127−139.

[1]Hershey, A. D. et al. (2007) Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache, 47 (1), 73−80. doi: 10.1111/j.1526-4610.2007.00652.

[1]Quinzii, C. M. et al. (2010) Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ10 deficiency. FASEB J., 24 (10), 3733−3743.

[1]Dahri, M., Tarighat-Esfanjani, A., Asghari-Jafarabadi, M. & Hashemilar, M. (2019) Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers. Nutr. Neurosci., 22 (9), 607−615.

[1]Sazali, S., Badrin, S., Norhayati, M. N. & Idris, N. S. (2021) Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis. BMJ Open, 11 (1), e039358. doi: 10.1136/bmjopen-2020-039358.

[1]Parohan, M., Sarraf, P., Javanbakht, M. H., Ranji-Burachaloo, S. & Djalali, M. (2020) Effect of coenzyme Q10 supplementation on clinical features of migraine: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutr. Neurosci., 23 (11), 868−875.

[1]Parohan, M., Sarraf, P., Javanbakht, M. H., Foroushani, A. R., Ranji-Burachaloo, S. & Djalali, M. (2021) The synergistic effects of nano-curcumin and coenzyme Q10 supplementation in migraine prophylaxis: a randomized, placebo-controlled, double-blind trial. Nutr. Neurosci., 24 (4), 317−326. doi: 10.1080/1028415X.2019.1627770.

[1]Gross, E. C., Lisicki, M., Fischer, D., Sándor, P. S. & Schoenen, J. (2019) The metabolic face of migraine − from pathophysiology to treatment. Nat. Rev. Neurol., 15 (11), 627−643.

[1]Cavestro, C., Bedogni, G., Molinari, F., Mandrino, S., Rota, E. & Frigeri, M. C. (2018) Alpha-lipoic acid shows promise to improve migraine in patients with insulin resistance: a 6-month exploratory study. J. Med. Food, 21 (3), 269−273.

[1]Rezaei Kelishadi, M., Alavi Naeini, A., Askari, G., Khorvash, F. & Heidari, Z. (2021) The efficacy of alpha-lipoic acid in improving oxidative, inflammatory, and mood status in women with episodic migraine in a randomised, double-blind, placebo-controlled clinical trial. Int. J. Clin. Pract., 75 (9), e14455.

[1]Traina, G. (2016) The neurobiology of acetyl-L-carnitine. Front. Biosci. (Landmark Ed.), 21 (7), 1314−1329. doi:10.2741/4459

[1]Hagen, K. et al. (2015) Acetyl-l-carnitine versus placebo for migraine prophylaxis: A randomized, triple-blind, crossover study. Cephalalgia, 35 (11), 987−995.

[1]Amini, L., Yaghini, O., Ghazavi, M. & Aslani, N. (2021) L-Carnitine versus propranolol for pediatric migraine prophylaxis. Iran. J. Child. Neurol., 15 (2), 77−86.

[1]Kabbouche, M. A., Powers, S. W., Vockell, A. L., LeCates, S. L. & Hershey, A. D. (2003) Carnitine palmityltransferase II (CPT2) deficiency and migraine headache: two case reports. Headache, 43 (5), 490−495.

[1]Hsu, C. C. et al. (1995) CPEO and carnitine deficiency overlapping in MELAS syndrome. Acta Neurol. Scand., 92 (3), 252−255.

[1]Charleston, L. 4th, Khalil, S. & Young, W. B. (2021) Carnitine responsive migraine headache syndrome: case report and review of the literature. Curr. Pain Headache Rep., 25 (4), 26.

[1]Panconesi, A. (2008) Serotonin and migraine: a reconsideration of the central theory. J. Headache Pain, 9 (5), 267−276.

[1]Nicolodi, M. & Sicuteri, F. (1996) Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Adv. Exp. Med. Biol., 398, 373−379.

[1]De Benedittis, G. & Massei, R. (1985) Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs. placebo. J. Neurosurg. Sci., 29 (3), 239−248.

[1]Ribeiro, C. A. (2000) L-5-Hydroxytryptophan in the prophylaxis of chronic tension-type headache: a double-blind, randomized, placebo-controlled study. For the Portuguese Head Society. Headache, 40 (6), 451−456.

[1]Sanders, A. E., Shaikh, S. R. & Slade, G. D. (2018) Long-chain omega-3 fatty acids and headache in the U.S. population. Prostaglandins Leukot. Essent. Fatty Acids, 135, 47−53.

[1]Sadeghi, O., Maghsoudi, Z., Khorvash, F., Ghiasvand, R. & Askari, G. (2015) The relationship between different fatty acids intake and frequency of migraine attacks. Iran. J. Nurs. Midwifery Res., 20 (3), 334−339.

[1]von Schacky, C. (2021) Importance of EPA and DHA blood levels in brain structure and function. Nutrients, 13 (4), 1074. doi:10.3390/nu13041074.

[1]Maghsoumi-Norouzabad, L., Mansoori, A., Abed, R. & Shishehbor, F. (2018) Effects of omega-3 fatty acids on the frequency, severity, and duration of migraine attacks: a systematic review and meta-analysis of randomized controlled trials. Nutr. Neurosci., 21 (9), 614–623.

[1]Soares, A. A., Louçana, P. M. C., Nasi, E. P., Sousa, K. M. H., Sá, O. M. S. & Silva-Néto, R. P. (2018) A double-blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA ɷ-3) for the prevention of migraine in chronic migraine patients using amitriptyline. Nutr. Neurosci., 21 (3), 219−223.

[1]Guu, T. W. et al. (2019) International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder. Psychother. Psychosom., 88 (5), 263−273.

[1]Clayton, P., Hill, M., Bogoda, N., Subah, S. & Venkatesh, R. (2021) Palmitoylethanolamide: a natural compound for health management. Int. J. Mol. Sci., 22 (10), 5305.

[1]Greco, R. et al. (2022) The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain. Headache, 62 (3), 227−240.

[1]Gabrielsson, L., Mattsson, S. & Fowler, C. J. (2016) Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. Br. J. Clin. Pharmacol., 82 (4), 932−942.

[1]Chirchiglia, D. et al. (2018) Effects of add-on ultramicronized N-palmitol ethanol amide in patients suffering of migraine with aura: a pilot study. Front. Neurol., 9, 674.

[1]Hernández, A. G. (2022) Palmitoylethanolamide-based nutraceutical Calmux® in preventive treatment of migraine. Clin. Neurol. Neurosurg., 218, 107 282.

[1]Andersen, L. P., Gögenur, I., Rosenberg, J. & Reiter, R. J. (2016) The safety of melatonin in humans. Clin. Drug Investig., 36 (3), 169−175.

[1]Kozak, H. H. et al. (2017) Sleep quality, morningness-eveningness preference, mood profile, and levels of serum melatonin in migraine patients: a case-control study. Acta Neurol. Belg., 117 (1), 111−119.

[1]Zielonka, D. (2021) Melatonin secretion in migraine patients: the current state of knowledge. Neurol. Neurochir. Pol., 55 (1), 5−7.

[1]Rios, E. R. et al. (2010) Melatonin: pharmacological aspects and clinical trends. Int. J. Neurosci., 120 (9), 583−590.

[1]Sullivan, D. P. (2022) Furthering the understanding of behavioral aspects of sleep and headaches: another piece of the puzzle. Sleep, 45 (5), zsac012.

[1]Aaltonen, K., Hämäläinen, M. L. & Hoppu, K. (2000) Migraine attacks and sleep in children. Cephalalgia, 20 (6), 580−584.

[1]Long, R., Zhu, Y. & Zhou, S. (2019) Therapeutic role of melatonin in migraine prophylaxis: A systematic review. Medicine (Baltimore), 98 (3), e14099.

[1]Gelfand, A. A., Ross, A. C., Irwin, S. L., Greene, K. A., Qubty, W. F. & Allen, I. E. (2020) Melatonin for acute treatment of migraine in children and adolescents: a pilot randomized trial. Headache, 60 (8), 1712−1721.

[1]Crichton, M. et al. (2022) Orally consumed ginger and human health: an umbrella review. Am. J. Clin. Nutr., 115 (6), 1511−1527.

[1]Chen, L. & Cai, Z. (2021) The efficacy of ginger for the treatment of migraine: A meta-analysis of randomized controlled studies. Am. J. Emerg. Med., 46, 567−571.

[1]Martins, L. B. et al. (2020) Double-blind placebo-controlled randomized clinical trial of ginger (Zingiber officinale Rosc.) in the prophylactic treatment of migraine. Cephalalgia, 40 (1), 88−95.

[1]Martins, L. B., Rodrigues, A. M. D. S., Rodrigues, D. F., Dos Santos, L. C., Teixeira, A. L. & Ferreira, A. V. M. (2019) Double-blind placebo-controlled randomized clinical trial of ginger (Zingiber officinale Rosc.) addition in migraine acute treatment. Cephalalgia, 39 (1), 68−76. doi: 10.1177/0333102418776016.

[1]Delaruelle, Z. et al. (2018) Male and female sex hormones in primary headaches. J. Headache Pain, 19 (1), 117.

[1]Shuster, L. T., Faubion, S. S., Sood, R. & Casey, P. M. (2011) Hormonal manipulation strategies in the management of menstrual migraine and other hormonally related headaches. Curr. Neurol. Neurosci. Rep., 11 (2), 131−138.

[1]Molla, M. D., Hidalgo-Mora, J. J. & Soteras, M. G. (2011) Phytotherapy as alternative to hormone replacement therapy. Front. Biosci. (Schol. Ed.), 3 (1), 191−204.

[1]Burke, B. E., Olson, R. D. & Cusack, B. J. (2002) Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomed. Pharmacother., 56 (6), 283−288.

[1]Ferrante, F., Fusco, E., Calabresi, P. & Cupini, L. M. (2004) Phyto-oestrogens in the prophylaxis of menstrual migraine. Clin. Neuropharmacol., 27 (3), 137−140.

[1]Dzator, J. S. A., Howe, P. R. C., Coupland, K. G. & Wong, R. H. X. (2022) A randomised, double-blind, placebo-controlled crossover trial of resveratrol supplementation for prophylaxis of hormonal migraine. Nutrients, 14 (9), 1763.

[1]Cámara-Lemarroy, C. R., Rodriguez-Gutierrez, R., Monreal-Robles, R. & Marfil-Rivera, A. (2016) Gastrointestinal disorders associated with migraine: A comprehensive review. World J. Gastroenterol., 22 (36), 8149−8160.

[1]Gonzalez, A., Hyde, E., Sangwan, N., Gilbert, J. A., Viirre, E. & Knight, R. (2016) Migraines are correlated with higher levels of nitrate-, nitrite-, and nitric oxide-reducing oral microbes in the American Gut Project Cohort. mSystems, 1 (5), e00105-16.

[1]Gasbarrini, A. et al. (2000) Association between Helicobacter pylori cytotoxic type I CagA-positive strains and migraine with aura. Cephalalgia, 20, 561–565.

[1]Tunca, A., Türkay, C., Tekin, O., Kargili, A. & Erbayrak, M. (2004) Is Helicobacter pylori infection a risk factor for migraine? A case-control study. Acta Neurol. Belg., 104, 161–164.

[1]Faraji, F., Zarinfar, N., Zanjani, A. T. & Morteza, A. (2012) The effect of Helicobacter pylori eradication on migraine: a randomized, double blind, controlled trial. Pain Physician, 15, 495–498.

[1]Arzani, M. et al. (2020) Gut-brain axis and migraine headache: a comprehensive review. J. Headache Pain, 21 (1), 15.

[1]Sensenig, J., Johnson, M. & Staverosky, T. (2001) Treatment of migraine with targeted

nutrition focused on improved assimilation and elimination. Altern. Med. Rev., 6 (5), 488−494.

[1]de Roos, N. M., Giezenaar, C. G., Rovers, J. M., Witteman, B. J., Smits, M. G. & van Hemert, S. (2015) The effects of the multispecies probiotic mixture Ecologic®Barrier on migraine: results of an open-label pilot study. Benef. Microbes, 6 (5), 641−646.

[1]Martami, F. et al. (2019) The effects of a multispecies probiotic supplement on inflammatory markers and episodic and chronic migraine characteristics: A randomized double-blind controlled trial. Cephalalgia, 39 (7), 841−853.

[1] Tarighat Esfanjani, A., Mahdavi, R., Ebrahimi Mameghani, M., Talebi, M., Nikniaz, Z. & Safaiyan, A. (2012) The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis. Biol. Trace Elem. Res., 150 (1−3), 42−48.

[1] Maizels, M., Blumenfeld, A. & Burchette, R. (2004) A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache, 44 (9), 885−890.

[1]Dib, M. (2008) Optimizing prophylactic treatment of migraine: Subtypes and patient matching. Ther. Clin. Risk Manag., 4 (5), 1061−1078. doi:10.2147/tcrm.s3983.

[1]Barrow, M., Bell, L. & Bell, C. (2020) Transforming personalized nutrition practice. Nutr. Rev., 78 (12), 1046−1051. doi:10.1093/nutrit/nuaa012.

[1]Martin, B. R. & Seaman, D. R. (2015) Dietary and lifestyle changes in the treatment of a 23-year-old female patient with migraine. J. Chiropr. Med., 14 (3), 205−211.